Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587951 | 0.94 | MAPT (0.43) | MAPTHTTMAPK1DRD2DRD3 | |
| SCHEMBL1778958 | 0.88 | MAPT (0.44) | MAPTHTTMAPK1DRD2DRD3 | |
| SCHEMBL4588156 | 0.83 | HTR7 (0.41) | MAPTHTTMAPK1DRD2DRD3 | |
| SCHEMBL1779662 | 0.82 | MAPT (0.45) | MAPTHTTMAPK1DRD2DRD3 | |
| SCHEMBL4587250 | 0.82 | MAPT (0.52) | MAPTHTTMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL4586867 | 0.82 | KCNH2 (0.46) | MAPTHTTMAPK1DRD2SMN1; SMN2 | |
| SCHEMBL4588966 | 0.81 | MAPT (0.47) | MAPTHTTMAPK1DRD2SMN1; SMN2 | |
| SCHEMBL1778625 | 0.80 | CCR2 (0.50) | MAPTHTTMAPK1DRD2DRD3 | |
| SCHEMBL1779616 | 0.77 | MAPT (0.48) | MAPTHTTMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL1779615 | 0.77 | MAPT (0.48) | MAPTHTTMAPK1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | CCR2, CCR5, CCL2 | MAPT 4777/4885HTT 4706/4885MAPK1 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.